<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-six children with B-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) or Murphy Stage III or IV B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) progressed or relapsed after first-line therapy with a short, intensive multiagent chemotherapy regimen [United Kingdom <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">Childhood Cancer</z:e> Study Group (UKCCSG) 9003] (n = 62) or a slightly less intensive regimen (UKCCSG 9002) (n = 112) </plain></SENT>
<SENT sid="1" pm="."><plain>Eight patients (4.6%) never achieved complete remission (CR) and 18 (10.3%) relapsed </plain></SENT>
<SENT sid="2" pm="."><plain>Second-line therapy resulted in remission for eight patients (30%) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients initially treated with the 9003 protocol died </plain></SENT>
<SENT sid="4" pm="."><plain>Three patients (11.5%) in the 9002 group, including one who never achieved CR in the primary site, are alive after second-line therapy </plain></SENT>
<SENT sid="5" pm="."><plain>This study confirms that the prognosis of relapsed or refractory <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>/B-NHL is poor and exceptionally so if relapse occurred less than 6 months from diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>High-dose therapy with stem cell rescue was used in only seven patients; its role needs to be studied further </plain></SENT>
</text></document>